Michael Secora - Feb 9, 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Financial Officer
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Feb 9, 2024
Transactions value $
-$25,346
Form type
4
Date filed
2/13/2024, 07:01 PM
Previous filing
Jan 18, 2024
Next filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +8.66K +0.88% $0.00 990K Feb 9, 2024 Direct F1
transaction RXRX Class A Common Stock Award $0 +174K +17.6% $0.00 1.16M Feb 9, 2024 Direct F2
transaction RXRX Class A Common Stock Tax liability -$25.3K -2.51K -0.22% $10.09 1.16M Feb 9, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Award $0 +348K $0.00 348K Feb 9, 2024 Class A Common Stock 348K $10.09 Direct F8
holding RXRX Stock Option (Right to Buy) 685K Feb 9, 2024 Class A Common Stock 0 $2.22 Direct F4
holding RXRX Stock Option (Right to Buy) 1.04M Feb 9, 2024 Class A Common Stock 0 $2.22 Direct F5
holding RXRX Stock Option (Right to Buy) 117K Feb 9, 2024 Class A Common Stock 0 $11.14 Direct F6
holding RXRX Stock Option (Right to Buy) 3.91K Feb 9, 2024 Class A Common Stock 0 $11.14 Direct
holding RXRX Stock Option (Right to Buy) 405K Feb 9, 2024 Class A Common Stock 0 $8.55 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This RSU vested immediately upon the grant date.
F2 This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2024 and every three months thereafter.
F3 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F4 The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
F5 The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
F6 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F7 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F8 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.